Subscribe to ShareProphets to access Premium Content

The most read non-Quiz, non-Tom article last week is by Steve Moore, Aptamer: “pleased to announce” proposed fundraise and board changes – a big 'up your’s' to investors from the not-long-ago 117p per share IPO!, at No 2 or No 5 including Bearcasts.

Thanks for all the kind wishes about my health and that of Joshua, we seem to be on the mend. In today's podcast I discuss Kefi Gold & Copper (KEFI), Skinbiotherapeutics (SBTX), Argo Blockchain (ARB) and - in detail - Victoria (VCP) 

On developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, OptiBiotix Health (OPTI) we’ve previously noted ‘some delays in delivery but a sales recovery Buy’ – including with “product launches by Apollo Pharmacies in India and restocking by some partners with sales normalising… as in previous years, there was no contribution in this period from licence or royalty payments which tend to be received in the second half”. We’ve since again spoken to CEO Steve O'Hara.

OptiBiotix Health (OPTI), a developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, has recently provided an update presentation on its commercial strategy and future plans. At a current 19p, the shares are at least up from 16.5p lows last month but remain well down from above 30p as recently as August and 46p at the start of this year and we’ve spoken to CEO Steve O'Hara.

Even Pete Brailey the most staunchest of Tory members you could ever meet says he has given up on the party after today's budget. I go through two lies Jeremy Hunt told and consider how he has screwed the poor, those of us running SMEs and is protecting super rich folks with sons at Eton with another lie.  Like Peter I shall not vote Tory next time.  Then onto a man who is not a liar, Optibiotix (OPTI) boss Steve O'Hara and the presentation he gave today which is below. I mention Skinbiotherapeutics (SBTX) and an email exchange today at this point. Then a few words on Kefi Gold & Copper (KEFI) follow then on to Argo Blockchain (ARB) which I expect to go bust next week and Ceres Power (CWR) whose valuation is still bonkers despite the shares slumping by 80% since peak ramp. 

OptiBiotix Health (OPTI) has announced Nahdi Medical Co has received approval from the Saudi Food and Drug Authority for GoFigure shakes and bars and that it has received the first purchase order from Nahdi.

OptiBiotix Health (OPTI) has announced what it states is an important extension of its commercial experience and reach in the Asia Pacific region – with an agreement with Nutraconnect Pte., Ltd to develop and implement a market strategy there.

These are the most-read articles and most listened-to Bearcasts of the week. The most read non-Tom non Darren article is “The Gold View From The Montana Log-Cabin As The Fed Is In A Jackson’s Hole” by Nigel Somerville at number 5 or number 11 if you include Bearcasts.

Let us be clear. When I said that Staurt Ashman said that month on month sales doubled in both July and August I said so because the bearded loon said so in an email to me. For him to backtrack as he does in this interview and suggest that "Mr Angry" is a bit confused, therefore makes me a bit more er....angry. If you have an hour of your life to spare, enjoy.

In today's bearcast I look in detail at Cake Box (CBOX), nanosynth (NNN) and Skinbiotherapeutics (SBTX). 

OptiBiotix Health (OPTI) has announced that it now expects half-year sales in its new structure to be materially lower than expected and, though it expects sales normalising in the second half and healthy growth next year, the current year is to now be “insufficient to make up the H1 deficit”. We profusely apologise for the short-term disappointment though, having spoken to the company, what to do now with the shares down at 20p to buy, a £17.6 million market cap?

If Steve Holdsworth has not passed away as I was told I hope he enjoys what I have to say about him. If he has that is my greatest loss today although I do also discuss Optibiotix (OPTI) and Skinbiotherapeutics (SBTX) in detail, the two battering the value of my pension fund. I won't push Steve O' Hara in the River at Sharestock but if he brings his chairman I'd be tempted. Grilling O'Hara in person over a Wrexham lager is surely another reason for you to book HERE. The number of seats now needed: 74. Join the crowd on September 10. I discuss Red Rock Resources (RRR), Allied Minds (ALM), Canadian Overseas Petroleum (COPL) and, on behalf of a convalescing Nigel Somerville, Haydale Graphene (HAYD). 

I start with a reference to this personal podcast about Christmas Day 1914 HERE. Then it is onto Ironveld Resources (IRON), Kefi Gold & Copper (KEFI), Skinbiotherapeutics (SBTX), Advanced Oncotherapy (AVO) and Argo Blockchain (ARB) and it is one of two more reasons give to book your seats at ShareStock on September 10 NOW HERE

I start with the trials of ordering portable loos for ShareStock which I have now done. More than 40% of the seats are now taken so with 7 weeks to go please book yours HERE. Then onto how Barclays (BARC) may strand me in Greece and why the Mrs reckons I am wrong on how gay is your stockbroker. Then it is onto Skinbiotherapeutics (SBTX), Optibiotix (OPTI), Ben's Creek (BEN) and Advanced Oncotherapy (AVO).

OptiBiotix Health (OPTI) has announced an update on recent scientific and commercial activities, emphasising it is “increasing the range of products, applications, and territories creating the potential to open larger market opportunities”.

Writing on OptiBiotix Health (OPTI) last month with the shares at 21p to buy, we noted clear news flow potential to spark the shares.  We drank our own medicine with Tom Winnifrith buying more shares in the market at c22p. They are now further up at 37p on the back of a “Joint development agreement signed with Firmenich”-titled announcement.

We're halfway through the year, and that gives us a little time to reflect back on the most-listened-to Bearcasts of this past six months. 

We're halfway through the year, and that gives us a little time to reflect back on the most-read stories of this past six months. Who would have guessed THIS would be #1?

These are the most-read articles and most listened-to Bearcasts of the week. The most read non-Tom article is Ariana Resources – News Soon To Add Value? You bet! BUY by Nigel Somerville at number six or number 12 if you include Bearcasts.

I am more panicked by the IRA man objecting to my bonfire. Heck, it is not as if it were the 12th July, and I were wearing my bowler hat with an orange sash, is it? In today's podcast, I look at Skinbiotherapeutics (SBTX); Eurasia (EUA) and a Kraut moron; Supply@ME Capital (SYME); and Argo Blockchain (ARB). 

Listen to the 20 most listened-to Bearcasts since January 1st and you'll hear nearly seven hours of Tom's dulcet tones unwinding the unexplainable, embarrassing the shameless, and chiding the ridiculous (Music Magpie holders? Chill Brands RNS's?) Plus cats, gardening, and, if I heard these correctly, life as a single mother.

These are the most-read articles and most listened-to Bearcasts of the week. The fact that BREAKING: Darren Atwater Resignation letter is the most read article this week quite disturbs me: were ShareProphets readers thrilled or dismayed at the news? (It was, of course, an April Fools.) The most read non-Tom story is Friday news I missed last week from Rolls-Royce and Imperial Brands by Chris Bailey at Number 10 or Number 16 if you include Bearcasts.

Shares are now ‘ex-dividend’ for Optibiotix’s ‘ProBiotix Health’ business, which will be spun off onto the AQSE Growth Market – with an associated fundraise – at the end of this month. Additionally, SkinBioTherapeutics (SBTX), in which it has a 20.73% stake, has just announced half-year results – that the market did not like. So, how does the valuation stack up now?

Apparently, the chap from the FT may object to me reminding those at the April 5 Woodford event that his paper, like the wretched Mail on Sunday, Daily Mail, Sunday Times et al DID suck Woodford’s PR cock.  Elsewhere, I discuss Red Rock Resources (RRR); Skibiotherapeutics (SBTX); Amigo (AMGO); Avacta (AVCT); Inspirit (INSP); and Mirriad Advertising (MIRI).

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

I start with Mello Events, which last night exposed itself as a PR promoter, failing to allow any questions about the elephant in the room: musicMagpie(MMAG).  Then to Optibiotix (OPTI) and Skinbiotherapeutics (SBTX), after today’s news from the latter. I have spoken to both Steve O’Hara and Stuart Ashman. As Les points out in the comments section, the silver lining for you is the postponement of my retirement – but not for long. The market has over-reacted: long-term, these two companies will subsidise the goat farm, as I explain in detail.

This is a very long podcast, covering: Optibiotix (OPTI); Skinbiotherapeutics (SBTX); Kefi (KEFI); Bluebird (BMV); Ten Lifestyle (TENG); CakeBox (CBOX); Deepverge (DVRG); Petropavlovsk (POG); Eurasia (EUA); and Amur Minerals (AMC).

Forgive the voice. Last week’s cold has left me sounding like I have been swallowing gravel. I start with a few words about distractions today which included ordering 72 blackthorn plants and 12 wild blackberry bushes and fetching antique Welsh furniture to go to Greece. Then I ponder whether Nigel is reinvesting his Ariana (AAU) dividends in Ariana (AAU).I explain why I am not and where I am putting the cash. Or  rather I am sitting on the fence between Optibiotix (OPTI) and Skinbiotherapeutics (SBTX). The 3x company I mentioned on Saturday, is a well known one and will be exposed via a multi-part series kicking off tomorrow at 8.30 AM and it is, I am sure, a zero.  Ahead of then I discuss what makes a real bear market and how it affects rubbish stocks out of cash. Until you see  a good few RNS statements each month saying that “shares are suspended pending clarification” you are not in a bear market.  In that vein, I mention three POS companies which RIGHT NOW have no cash and are burning it: Vast Resources (VAST), Chill Brands (CHLL) and Supply@ME Capital (FRAUD) and I discuss the next steps for that trio and why the net is tightening on them.

OptiBiotix Health (OPTI) has announced that it intends to seek admission of its ProBiotix Health business onto the AQSE Growth Market with an associated fund raise of approximately £2.5 million at an indicative premoney valuation of £22.5 million and a distribution in specie. With, at a 35.5p share price, OptiBiotix as a whole currently capitalised at £31.3 million, is this good news? You bet!

I do comment about Julie Meyer’s latest tweet. Suicide is no joking matter and this act alone should see her lose her MBE. But most of this podcast is about events today at Optibiotix (OPTI) whose core businessis not worth MINUS £12 million as Mr Market implies. Ahead of the 24th March FYB! A pedant points out that at 14 mins in I say Optibiotix shareholders will get a distribution of 36-38%of Skinbiotherapeutics – clearly  meant Probiotix. Apologies – long covid strikes again.

There was no Bearcast yesterday as I was a) knackered after a tough Rogue Bloggers for Woodlarks training walk and then b) a bit pissed after Ireland’s triumph over the infidels. You can now donate to the 2022 Rogue Bloggers walk on June 11 HERE. In today’s podcast I discuss Optibiotix (OPTI), a long chat with Steve O’Hara and an, in my view, mistaken, but for him massive, call by Lemming Investor. I also cover SkinBiotherapeutics (SBTX). The Russia/Ukraine podcast I refer to is HERE

I take a tour through four weekend press articles starting with that greedy scumbag Nigel Farage – I refer in the podcast to THIS PIECE. Then to two great pieces on Ukraine and on the decadent West by Peter Hitchens and Matthew Syed respectvely before discussing the Sunday Times article on CBD and pot stocks. Finally I discuss Chris Bailey’s excellent piece on this website and my own approach to shares I own, mentioning Skinbiotherapeutics (SBTX) and some news breaking in the USA.

OptiBiotix Health (OPTI) has issued a trading update commenting that 2021 “total invoiced sales for the group were £2.2m (2020: £1.5m) an increase of 46.7% on the previous year and in line with market expectations” and including that it “has made good progress against its stated aims of focusing on a smaller number of large partners in key strategic markets and expects to see the benefits of these in 2022 and beyond”. What does that mean at the bottom-line?

I start with Ukraine, Russia and all that macro shite and say afew things which challenge the Western narrative and which some of you may disagree with violently. I cover Ferrexpo (FXPO),Amur (AMC) and Eurasia (EUA) in this section. I mention Cineworld (CINE) and then discuss today’s news from Optibiotix (OPTI) and, en passant, Skinbiotherapeutics (SBTX) where I am buying more shares this afternoon. 

SkinBioTherapeutics (SBTX) has published a “Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!

These are the most-read articles and most listened-to Bearcasts of the week. The most-read article non-Tom article is once again by me, the ShareProphets Sunday Pub Quiz #128. The most-read non-Tom, non-Darren article is Thar’s Gold in Greenland’s Icy Mountains and this Fiesty Firm’s Out to Exploit it by Malcolm Stacey, making a welcome return to the leaderboard at number nine or number 16 including Bearcasts.

A reader says that he is tempted and I understand his reasoning but here is why I am not going down that route.

I want to be 100% transparent with you so I explain why, as of 8 AM today, Peter is no longer a member of this parish after apologising for yesterday’s poor sound quality for which there was a good reason. I look at two shocking economic statistics and what they mean. I then cover: SkinBiotherapeutics (SBTX), Bluebird Merchant Ventures (BMV),  AEX Gold (AEXG), Novacyt (NCYT), Avacta (AVCT) and Cake Box (CBOX). 

I am asked this question by a long suffering reader in relation to Skinbiotherapeutics (SBTX) and do my best to answer. I look at IQE (IQE),the curious share dealing of Mr Drew Nelson and whether I’d be tempted. I still see no sign of the IPO of Zak Mir’s crazy media investment company which he said was imminent two weeks ago. Is it Lift off?  I comment on Bluebird Merchant Ventures (BMV)  and then have a detailed look at Sarah Willingham’s Nightcap (NGHT) in light of today’s expose. It really is a one way bet. Down. 

I start with a few thoughts on a visit this morning to the post industrial wastelands of Salford. Gosh it was grim.  Then a schoolboy error on Skinbiotherapeutics (SBTX) but it only makes the case  for filling your boots stronger. No, I have not got a scooby about why Bluebird (BMV) shares are up but I speculated and put together a few pieces of the jigsaw.  I look at W Resources (WRES) but would not touch it with a bargepole and then discuss the wholly unacceptable greed of Andrew “piggy” Austin at Kistos (KIST)

As you know I am reviewing my pension as discussed HERE. As such I am chatting to various CEOs who I have backed and yesterday evening I had a long chat with Stuart Ashman of Skinbiotherapeutics (SBTX). He is not a bluffing promoter but, I believe, a sober and grounded chap. I came away from the call just incredibly excited. I explain why the share price is where it is but also why this could within a couple of years be a 10 bagger but it could equally be a 20 bagger. Certainly any free cash within my SIPP will, even at twice today’s price be going into this stock. And if I am right there is a clear implication for Optibiotix (OPTI) so I am not selling any shares in it either.  Footnote/correction. There are not 2 million psoriasis sufferers worldwide as per podcast but 120 million. I can’t say that weakens the case!

OptiBiotix Health (OPTI) has made what it describes as a “Commercial and strategy update”, including arguing “look forward with confidence to further commercial progress of the group in the current year and beyond”. What does that though mean tangibly?

OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LP_LDL - on a different population group of hypercholesterolemic adults – has shown “at six weeks, when volunteers taking placebo were compared to those taking LP_LDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.

Okay the crime is not as exciting as it sounds and was not, as far as I know, perpetrated by some Bulletin Board loon. After discussing that I look at Chill Brands (CHLL), Brave Bison (BBSN) and Skinbiotherapeutics (SBTX)

SkinBioTherapeutics (SBTX) has announced results for its year ended 30^th June 2021 emphasising “transformational” progress. So what is this?

I start with Joshua & Jaya’s advent calendar. Then I look at Tern (TERN), Toople (TOOP), Skinbiotherapeutics (SBTX) and Silverwood Brands (SLWD). 

In today’s podcast I discuss why I worry that my wife may have become a real housewife of posh Cheshire, not the part where they play rugby league. Then I look at ADM Energy (ADME) and that RNS reach issue again, tell you about a psychic moron who owns shares in Supply@ME Capital (SYME) and then I discuss, at length, Skinbiotherapeutics (SBTX) after a chat with CEO Stuart Ashman today and on the back of that I have bought more shares in the company.

I do not name the company but the dossier is one one of the journalists here. It concludes that he has done nothing wrong but it goes through utterly uncalled for very personal details about him, his world view, his girl friend, his work and more. It made my skin crawl and the company that spunked £40,000 on this document should be utterly ashamedof itself. I have put in a call and let it know that behaving like this towards one of our journalists is asking for a lot of trouble. It is repellant and I am on the warpath.  I then look at theSP Angel/Union Jack Oil (UJO) scandal, at Nanosynth (NNN), Powerhouse (PHE) explaining the RNS/RNS Reach issue in full.Finally I discuss Skinbiotherapeutics (SBTX). 

In today’s podcast I look at Vast Resources (VAST) and why you should read an RNS closely and at Supply@ME Capital (SYME) as I get my dates confused and so, it seems, does it. I consider Eurasia Mining (EUA) – surely a statement needed. I look at Skinbiotherapeutics (SBTX) and at Amigo (AMGO) where surely even Evil must concede defeat at the hands of the FCA on whose side I am on, in this matter at least.

The top non-Tom article this week is Oil and Gas– I think an inflection point has been reached: oil could hit $200 and here is why by Peter Bailey at number three or number eight if you include the Bearcasts. 

Having been falling from early this month, shares in SkinBioTherapeutics (SBTX) are currently further lower after it announced “OptiBiotix Health Plc has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share”. With SkinBioTherapeutics CEO Stuart Ashman though arguing “the company is going from strength to strength” and “it is important to attract new investors who are keen to come on board to support us in the next stage of the company’s development, as a commercial entity”, why the further share price fall?

I record from the Welsh Hovel which is once again a building site. Excuse any background noise. I look at Wildcat Petroleum (WCAT) and its uncorrected and untrue 4 October RNS. Then at the fraud Chill Brands (CHLL). In both cases the regulator, the hapless FCA, should be acting right now. Then it is onto Cineworld (CINE) and, with the graphic below – hat tip EB. I explain why its trading statement is so deceptive and why the shares are still a sell. Finally a few words on Optibiotix (OPTI) & Skinbiotherapeutics (SBTX) and today’s confirmation of what a good journalist I am. What does it mean for both stocks?

As predicted HERE the print going through late on Friday was Optibiotix (OPTI) dumping £2 million worth of Skinbiotherapeutics (SBTX) at 55p. I told you that this would happpen weeks ago producing more bluster and fake denials from all involved. Fuckers! The release this morning insults the intelligence of we loyal shareholders in both companies yet again. Stuart, Steve, posh PR bird Melanie Toyne-Sewell and the scumbags at Cenkos do you think we are idiots? You treat us as if we are.

I predicted that this was the plan and such a trade went through on the prints late on Friday. Both Optibiotix (OPTI) and Skinbiotherapeutics (SBTX) have declined chances I have offered ( two for Opti) to deny the trade was as I speculate. So where does this leave shareholders in both companies and the, badly advised by scumbags Cenkos, Steve O’Hara?  

SkinBioTherapeutics (SBTX) has announced it has commercially launched its probiotic food supplement to help alleviate the symptoms associated with psoriasis, AxisBiotix-Ps.

I start with the two companies beginning with V and articles on this website today: Versarien (VRS) has responded, weakly to this expose. Vast Resources (VAST) cannot respond to this bombshell which exposes the cancer at the heart of AIM Regulation again and makes the shares uninvestable at any price. Then I look at Ben’s Creek (BEN), Skinbiotherapeutics (SBTX) on product launch day and at Central Copper where an IPO that should be pulled is delayed again. 

I start with a few notes on horticulture here in Wales then move onto questioning my strongly held belief that Supply@ME Capital (SYME) is a worthless fraud. Then I explain why the recent Cenkos note on Skinbiotherapeutics (SBTX) is wrong and how, via its website, the company faces an acid test. Actually the website I refer to has now been amended as you can see HERE. But not before my contact placed an order.  Finally I look at Vast Resources (VAST) and its shocking placing followed by even more shocking no-one is watching O’clock results.

I deal with Skinbiotherapeutics (SBTX) first.  Then it is onto Yourgene (YGEN) and its trading statement, Eurasia (EUA) and a two year farce and finally the bid for Arden (ARDN) by Ince Group (INCE) and what to make of it all. I feel uncomfortable for reasons I explain.

In today’s Bearcast, I look at Skinbiotherapeutics (SBTX), Optibiotix (OPTI), Kefi (KEFI), Nightcap (NGHT), VAST Resources (VAST) and finally at my old pal Richard Poulden’s Valereum Blockchain (VLRM), the current love interest of Big Dave Lenigas. 

I have a few words on Malcolm’s article of earlier which, by definition, makes me old according to him. Pot. Kettle. I talk about the general mood of insanity. Then, in that context, I look at the Optibiotix (OPTI) vs Skinbiotherapeutics (SBTX) debate. Should one short one and go long the other as PL has suggested? I discuss what I am doing and why.

Life sciences compounds developer OptiBiotix Health (OPTI) has announced results for the first of calendar 2021, emphasising “sales of LP_LDL and SlimBiome of £1.076m, a 44.5% increase over H1:2020… pleasing given the continued uncertain global economic environment and challenges of the subsequent waves of COVID-19, particularly in countries like India and the USA”. The shares have currently responded slightly higher, to 50p.

As things stand at 69p, we are 289% ahead on this share tip but there is much more to come. SkinBioTherapeutics (SBTX) has announced its probiotic food supplement to help alleviate the symptoms of psoriasis, AxisBiotix-Ps, is to launch on 29^th October, following highly positive results from its consumer study in May and key commercialisation activities since.

This event was held on 9 September and what follows is a transcript of the more interesting Q&As. There is oodles of jam tomorrow but I sense that the time for that working has passed. Steve O’Hara and Optibiotix (OPTI) need to start delivering jam today to drive a re-rate of any sort, let alone from £50 million to £1 billion as suggested in Q1.

SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30^th June year-end cash totalled £4.6 million. Sounds good.

I discuss two developments at the Welsh Hovel. There is great news HERE but also a bit of a disaster which could have been fatal for the cats and bad for me. Then I look at backing proven failures or chaps who wave red flags mentioning Sensyne (SENS), Nigel Wray, me and a few others. That leads me on to the wall of silence from Central Copper Resources about its AIM IPO and me explaining what is really going on, notably at broker Brandon Hill. Finally I look at today’s news from Skinbiotherapeutics (SBTX) and where, as a result, I expect its shares to be at Christmas.

OptiBiotix Health (OPTI) has made a “Trading and commercial update” including that sales are ahead of its expectations for the first six months of the year and that it “believes it is in a strong position to meet or exceed its full year sales forecast”. The shares have currently responded up to 49.5p but there looks much further to go.

I start with a discussion on the forest fires in this region of Greece then move onto the impending total humiliation of Julie “Lingerie on Expenses” Meyer after today’s shocker HERE. Then I look at Supply@ME Capital (SYME) asking if its boss owns any shares at all. He certainly does not own 26% as claimed. Then I look at the Optibiotix (OPTI) trading statement  discussing it and Skinbiotherapeutics (SBTX). Finally back to a wretch: Versarien (VRS) and its shite results which show why we must get Ian Westbrook over the line – he is now, with a slightly extended deadline – just £1775 shy of making the loathsome Neill Ricketts sweat in court. Please keep giving those tenners and twenties HERE

OptiBiotix Health (OPTI) has announced its 2020 calendar year results, emphasising improving financials and that it is well placed to exploit a now established low overhead, sustainable business model. It is what we learned in a chat with Steve O’Hara that makes us flag this up as such a STRONG BUY.

SkinBioTherapeutics (SBTX) has announced the results of the AxisBiotix-PsT consumer study of patients suffering from psoriasis and it says that it will now be seeking regulatory approval for the product as a food supplement in parallel in the UK, US and Europe… targeting a commercial launch of theAxisBiotix-Ps™ product in Q4 2021”.  Do the maths! This is going to be massive.

Okay, tomorrow is the big day. If you are yet to donate please do so HERE as the Rogue Bloggers are now just over £2,000 off target. In today’s podcast, I discuss at length issues arising from the Skinbiotherapeutics (SBTX) and Optibiotix (OPTI) issue where Steve O’Hara says a man who took a company to the Isle of Man knows nothing about tax! Then onto the fraud Zoetic (ZOE), company specific issues and the wider one, raised by promoter David Lenigas today, of the increased risk caused by margin buying of small caps.

The good news is that Rogue Bloggers for Woodlarks is, 3 days ahead of our walk, now less than £3,000 away from our £48,000 fund raise target. If you are yet to donate, please do so HERE. In today’s podcast, I discuss Amigo (AMGO), Wishbone Gold (WSBN), Zoetic (ZOE), Skinbiotherapeutics (SBTX) and Optibiotix (OPTI).

Oh dear. What have I been accused of now? All is revealed in the photos below. I end by thanking you all as we are now at nearly £40,000 for Rogue Bloggers for Woodlarks. Thanks to all who have donated. To those still to chip in, as we are just c£8,000 short, please do so HERE. Sunday’s training walk will be the most grim yet. In the podcast, I look at Amigo (AMGO), Evil Knievil’s “scum” comment, Hurricane Energy (HUR), Skinbiotherapeutics (SBTX) and Novacyt (NCYT).

Noting that “there is now an extensive growing body of research demonstrating direct links between the microbiome and the immune system, and consequently skin health”, SkinBioTherapeutics (SBTX) announced, a couple of weeks ago, initiation of a research programme with the University of Manchester. This is good news but not the elephant in the room!

I start with a few words on the late Phil the Greek and reference an article I wrote exactly one month ago HERE on the liberal US celeb Joy Behar calling out Phil and his family as Nazis.  I reflect on the weather here in Wales and how tomorrow’s 20 mile training walk for Woodlarks will be very unpleasant indeed. So please do support me with a donation HERE. Then I discuss the saintly Vin Murria and share sales at Summerway (SWC) and for the first and last time in history I am a bit uneasy about all of this. Then the debate on whether to back the Skinbiotherapeutics (SBTX) or the Optibiotix (OPTI) charger? 

Noting that “there is now an extensive growing body of research demonstrating direct links between the microbiome and the immune system, and consequently skin health”, SkinBioTherapeutics (SBTX) has announced initiation of a research programme with the University of Manchester.

I start with a true story. Surely it is a cracking warning of the top of the market. Then onto the fraud Supply@ME Capital (SYME) confirming my scoop. Finally a long discussion on the morality of breaking lock-ins ref Optibiotix (OPTI), Skinbiotherapeutics (SBTX) and Powerhouse Energy (PHE) run by sleazy ex Tory MP Tim Yeo.

Notwithstanding the lock-in shenanigans with Optibiotix (OPTI) discussed HERE, I am more bullish than ever. The results from Skinbiotherapeutics (SBTX) for the six months to 31 December 2020 came out on Monday. I apologise for the delayed update but I needed to ponder a while. What we read a few days ago was just excellent. Hence this upgrade.

Yesterday it was Skinbiotherapeutics (SBTX) which allowed Optibiotix (OPTI) to dump shares less than six months after announcing a firm lock in agreement lasting 12 months. Today it is Powerhouse Energy (PHE) showing that these announcements are utterly meaningless and investors cannot rely on them at all.

I think Optibiotix (OPTI) shares are very cheap as are those of Skinbiotherapeutics (SBTX) and am a loyal shareholder in both expecting to treble my money from here. Nor do I begrudge Optibiotix selling a few shares in Skinbiotherapeutics as it announced it had today as I imagine that will more than pay for a Nasdaq listing which may drive a re-rate. But I suggest that, in light of today’s events, a document signed by Steve O’Hara and Nomad and broker Cenkos is a worthless piece of toilet paper and both have legged over and deceived investors in Skinbiotherapeutics. Let me explain.

OptiBiotix Health (OPTI) has announced a “Commercial strategy update” which shows strong progress in its strategy to initially build sales and brand presence and then move up the value chain by selling more product than ingredients and commercialising further compounds. We’ve also had a catch up chat with CEO Steve O’Hara. This should be THE YEAR when profits come close to or exceed £1 million.

Don’t get me wrong, I like the Optibiotix (OPTI) meal substitute drinks and do actually feel better after just a few days of losing a meal a day and a week of near zero carbs and no booze at all. But a serving suggestion from one reader went down very badly. Elsewhere I look at Sabien Technology (SNT) and the fallout from l’affaire Julie Meyer, Skinbiotherapeutics (SBTX) and also at Provident Financial (PFG).

The most read non-Tom article this week is Gold Shares – It’s been a tough few months, but I sense we are near the bottom by Nigel Somerville at number four, or  number nine including Bearcasts and Tom’s new shareshow. Which one is the best of the week? Tell me in the comments.

A chap says he has made five hundred grand on Eurasia (EUA) so what does it matter if a few rules have been broken? I explain exactly why it matters and should matter even to him. Then I address why shares in Optibiotix (OPTI) are not reacting to the surging share price of Skinbiotherapeutics (SBTX). Natch I remain a loyal shareholder in both.

In today’s podcast I mention my planned Ha Ha then cover market madness, all the signs, Path Investments (PATH), Fast Forward (FFWD) and Skinbiotherapeutics (SBTX). And thanks for understanding about yesterday’s DOS attack.

I start with communications received by email and twitter. I sense attempted entrapment by shareholders in the fraud Supply@ME Capital (SYME). Then it is onto a speech by Debbie Gupta of the FCA and her failure to understand why her organisation is not fit for purpose.  Then to Nightcap (NGHT), Petra Diamonds (PDL), Mountfield (MOGP), Skibiotherapeutics (SBTX) and me being fat as described here.

A few words on the Budget then is Peterhouse staffed by woke loons or alt right freaks or both? I discuss in relation to Mountfield (MOGP). I look at Marchale (MAC), Iconic (ICON), Optibiotix (OPTI) and Skinbiotherapeutics (SBTX).

As a loyal shareholder I see nothing to shock me and a good bit to please. Specifically:

OptiBiotix Health (OPTI) has announced a trading update, emphasising “another year of progress… probiotic and functional fibre divisions achieving profitability”. The shares have though currently responded lower to 55.5p, so what’s the current situation here? We’ve spoken to Chief Executive Steve O’Hara and we believe that Mr Market has got this one wrong.

In today’s podcast I look at Remote Monitored Systems (RMS), Online Blockchain (OBC), Zoetic (ZOE), Zenith Energy (ZEN) - after today’s bombshell expose -  ADVFN (AFN), Optibiotix (OPTI) and Skinbiotherapeutics (SBTX).

I am a massive shareholder in Optibiotix (OPTI) and believe that I will do very well from my investment, where my average in price is c9p. The shares are now 61.5p mid and I think they will easily double from here within 18 months if not far sooner. But there can be no double standards here in the way that I cover companies, just because I own shares in them. I think the company has made a material accounting error which is also an own goal! Here’s why:

Having asked for readers tips for 2021 for the prize of 1/2 litre of Tom Winnifrith’s Greek Hovel olive oil (2021 harvest) HERE, the following is the first monthly update on performance (to be eligible needed to have selected, on a once per username basis, a buy & sell pick from the LSE or AIM casino and the stocks not to have been suspended at the commencement of 2021)…

And now from Wales, by just 30 yards, it is my new weekly video show. This costs 99p per episode, and you can either listen to, or watch, some sparky interviews with Staurt Ashman of Skinbiotherapeutics (SBTX) where I am 130% up in seven months but think the shares could 20 bag from here and bear raider Lucian Miers on macro economics his cooling feelings on cold and warming feelings on bitcoin and his big longs and shorts. Then there are a few thoughts on companies you must NOT own, including the latest nonsense from the scallywags at Powerhouse Energy (PHE).You can access the show HERE

Yesterday, I was offline from ShareProphets for most of the afternoon due to a snowstorm here in Canada that knocked out my Internet. Tom wanted to see some pictures, which you can see below. The third one is right in front of the house – that’s some guy who has drilled a hole and is ice fishing. At the time of the photo, he had not caught anything. Now, on to the most read articles.

Making SkinBioTherapeutics (SBTX) one of our three tips of the year 2021, we noted we considered it likely to make 2021 a breakthrough year, including with a planned first quarter human study for AxisBiotix™ targeting psoriasis and then, subject to a positive readout, commencing commercialisation. Already we now have an “Enrolment for AxisBiotix-PsT study commences” announcement and the shares are already massively higher than our 15.5p tip price at 29p. But you’d be mad to sell.

Today I look at three companies. I start with Skinbiotherapeutics (SBTX) where I ask if it is better to travel than to arrive? Then it is onto Sarah Willingham, Allenby Capital, The Sunday Times and their collective shame in the disgraceful AIM IPO of car crash in waiting Nightcap (NGHT). Finally I look at Sosandar (SOS).

Shares in this company, where I am a loyal shareholder, raced ahead to 33p on Friday.  The excitement was driven largely by a false rumour and in part, methinks, on a rumour that is true. This morning I had it confirmed that the false rumour was, er, false.

Yup, if he does an interview with me and my tough questions, shares in Optibiotix (OPTI) go down.  So, going forward, it is only those paid-for interviews with folks like Proactive. “Steve, is your schlonger enormous or gigantic? Why are your shares so cheap? etc etc.” Whatever, I apologise to you all for asking the odd question. Without my malign influence, Optibiotix would clearly be in the FTSE 100. I discuss this company’s prospects and also those of Skinbiotherapeutics (SBTX) where I am also a loyal shareholder. I look at Trainline (TRN), Online Blockchain (OBC) and Vast Resources (VAST).

In today’s podcast I look at Cineworld (CINE), Trainline (TRN), Novacyt (NCYT), Powerhouse Energy (PHE), Optibiotix (OPTI) and Skinbiotherapeutics (SBTX).

Skinbiotherapeutics (SBTX) boss Stuart Ashman until today held zero shares in the company. And he told us all that it had enough cash to last it until the end of next year at least.  And so now there is a £4 million placing and £500,000 open offer at 16p.  Mr Ashman can you see why I might be annoyed?

I am back here at last and allow a bit of time for personal matters. Then it is on to Optibiotix (OPTI), Skinbiotherapeutics (SBTX), Verditek (VDTK) and G3 Exploration (G3E)

I am in a bit of a rush as I prepare to head to Shipston on family business. But first I have to enjoy filling skips, making jam and gin and emptying the kitchen. Then I answer Malcolm’s question on target prices with reference to two companies you know well. Then it is onto the assumption made by dim Tories like Lucy Allan MP about how all members of certain industries would thrive without lockdown. I know the industry she refers to better than anyone and she’s talking horse. The same madness is demonstrated with the way the dim Tories chuck cash at Versarien (VRS), the folly of which I expose again today HERE.

OptiBiotix Health (OPTI) is “pleased to present… results for the six month period ended 30 June 2020” and we have had a chat with CEO Steve O’Hara…

Very excited shareholder Tom Winnifrith writes: On 26 May 2020, Steve and I tipped SkinBiotherapeutics (SBTX) at a 17.75p offer and at up to 20p with a target price of 30p. News last week suggests that, notwithstanding this company wasting a few grand a month employing the biggest knobhead in Christendom to do its PR, we were more than a tad conservative and the shares now trade at 22p-23.5p and are still dirt cheap.

SkinBioTherapeutics (SBTX) has updated that it is “very pleased with the progress that the company has been able to make during these most exceptional times”, particularly including “several months ahead of schedule, Winclove has now been able to successfully combine and formulate the blend as a probiotic food supplement, to be known as AxisBiotix ™Ps”...

There are only two financial journalists who write regularly about Skinbiotherapeutics (SBTX): myself and Steve Moore. Coverage elsewhere is minimal to zero yet for some reason the company wastes the cash of loyal shareholders such as myself, on Instinctif, a financial PR firm.  Yesterday at 4.16PM on trading statement day Mr Phillip Marriage of Instinctif dropped me an email. I suspect he wishes he had not.  Our full exchange follows.

And now from Wales, by just 30 yards, it is my new, I hope, weekly video show. This costs 99p per episode to access and you can either listen or watch very sparky interviews with our Gary Newman on mining stocks to buy, why gold is NOT going to soar, a compelling £1.7 billion non-mining short and fishing shares, Harry Adams the boss of Kefi (KEFI) - a stock I own - and myself on why Cineworld (CINE) deserves to go bust, wont, but is a stonking short none the less. You can access the show HERE

And now from Wales, by just 30 yards, it is my new, I hope, weekly show. This costs 99p per episode to access and you can either listen or watch very sparky interviews with our in house gold guru Nigel Somerville on why you must be in gold and on the stocks or ETFs to own to maximise your bull market gains and with Union Jack Oil (UJO) boss David Bramhill, the most underpaid oil CEO on AIM. I also serve up a red flag-spotting session with reference to Diversified Gas & Oil (DGOC). You can access the show HERE

Okay, with three days to go to my 33.3 mile walk in the Welsh rain we need just £9,000 more to ensure Woodlarks survives. Thanks to all who have donated. If you have not done so please do so now HERE.  In the show today I discuss Restaurant Group (RTN), Quiz (QUIZ), the disaster now facing property investors, Skinbiotherapeutics (SBTX), UK Oil & Gas (UKOG) and Photo-Me (PHTM) where the bosses are total bastards. How dare the greedy so and sos treat poor old Malcolm Stacey like this?.

The most read non-Tom article this week is Two Old Timers: Hochschild and Hertz... by Lucian Miers is just on the leaderboard at number ten or  way down at number 18 including Bearcasts and Tom's new shareshow.

Yesterday I explained how Optibiotix (OPTI) has sold 4.5 million shares in Skinbiotherapeutics (SBTX)  on Friday, a trade yet to be announced but where the buyer is clearly already selling. But this scandal is, I believe far, far bigger and should be enough to see SP Angel cold shouldered by the AIM Community.

I start with my training walk of yesterday for rogue bloggers for Woodlarks. i managed 12.5 laps before the sun got to me. In two weeks I must do 50. My next big walk is Tuesday - we are at 36% of target so please do donate HERE. Next up in hargreaves Lansdown (HL.), why not screw your customers as they seem to like it? Then onto share sales in Skinbiotherapeutics (SBTX) by Optibiotix (OPTI) and what appears to be a scandal involving broker SP Angel. I shall be going to the FCA tomorrow to ask for an enquiry. Finally is Steve O'Hara a liar like Lyin' James Draper of Bidstack (BIDS). Drunken Sailor who is suffering a GroupThink induced lockdown dementia thinks so and also that I am a ramper and should tell folks to sell. I discuss Drunken's concerns in light of a chat with O'Hara and an email from him which I read out.

In today's podcast I tempt fate - as I am about to record a video with Matt Earl - in defending Boohoo's (BOO) boss. I discuss the shares vs cash debate, Rolls Royce (RR.), sharp share price moves, ref Skinbiotherapeutics (SBTX) and what the real unemployment number will be as furloughing is wound down. And now for a long training walk for the Woodlarks walk in 2 weeks time. We are now at 36% of target: please donate today HERE

It has been announced OptiBiotix Health (OPTI) has sold 2.2 million further shares in 2017 spun-off onto AIM SkinBioTherapeutics (SBTX). This despite OptiBiotix’s results earlier this year including “SkinBiotherapeutics plc is making solid progress… As its partnership discussions turn into commercial agreements providing industry validation of its technology we anticipate SkinBiotherapeutics plc will grow in value, whereupon OptiBiotix shareholders will benefit from the appreciation of this asset”. So why the further sale?...

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following updates on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

The next City Forum is on January 21 with Adam Reynolds as the guest speaker being quizzed by the Sith Lord Zak Mir. I bet Adam's quaking about that grilling. Three companies will also present and take questions as will Adam. Put the date in your diary. From this week's seminar here is Skinbiotherapeutics (SBTX) presenting and taking questions.

There are now just ten seats left at the UK Investor Show team's next City forum which takes place on the evening of Monday 3rd December in the heart of the City of London at the headquarters of investment bank UBS. There’s mince pies, wine and canapes on offer but more importantly the event features presentations and a chance to quiz three growth companies: SkinBioTherapeutics, RiverFort Global Opportunities (formerly Paternoster Resources) and Sosandar. The evening ends with our own, Chris “Three Brains” Bailey, interviewing Britain's Buffett Nigel Wray.

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

Having reached circa 130p in August, shares in OptiBiotix Health (OPTI) have slid to 78p-81p. This is despite a pipeline of seemingly very significant deals likely to be converted and as such…

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

OptiBiotix (OPTI) has announced that it will be seeking shareholder approval to undertake a share capital re-organisation to allow the company to make future dividend payments. This is an accountancy matter - you can't pay dividends if you have retained losses. It is a clear statement of intent.

Actually I am in Greece on December 4 or at least on my way home after the olive harvest. But, in return for a small donation to Woodlarks, I have agreed to record a video from the Greek Hovel with a few market thoughts and a couple of share tips for Christmas.

The last Adam Reynolds placing was Skinbiotherapeutics. The next one is Orogen Gold  (ORO)where the company is raising money ahead of an RTO which will see it become an online retailer. I already held shares but we are quadrupling the size of our holding in the next placing. We are in big time.

There are some people who think the stockmarket and shares business is like robbing a bank - all about making money however you go about it. But at a time of year when many of us think about a man who gave the ultimate gift, his life, for others we think that business should also be about giving. And that brings us to Woodlarks and the UK Investor Show. It started with Paul Scott who donated his, very small, speaker fee...

OptiBiotix (OPTI) skin health-focused subsidiary, SkinBioTherapeutics, has successfully listed its shares on AIM. Good news as OptiBiotix still has a near 42% stake…

Tom Winnifrith’s ‘Golden Share’ (all proceeds to Woodlarks) from Saturday’s 2017 UK Investor Show has today listed on AIM – and it’s good news…

Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.